ADEF
MIRM icon

ABS Direct Equity Fund’s Mirum Pharmaceuticals MIRM Stock Holding History

ABS Direct Equity Fund’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$246K Sell
117
-1,983
-94% -$199K 0.15% 92
2026
Q1 		$222K Buy
+2,100
New +$198K 0.17% 74

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ABS Direct Equity Fund's MIRM Position: Q2 2026 in Review

ABS Direct Equity Fund reduced its Mirum Pharmaceuticals (MIRM) stake by 94% in Q2 2026, selling an estimated $199K and leaving 117 shares worth $246K. The position accounts for 0.15% of the portfolio, ranked #92.

ABS Direct Equity Fund first reported a position in MIRM in Q1 2026 and has held it in 2 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • ABS Direct Equity Fund held 117 shares of Mirum Pharmaceuticals worth $246K as of Q2 2026.
  • ABS Direct Equity Fund sold 1,983 Mirum Pharmaceuticals shares in Q2 2026, an estimated $199K.
  • Mirum Pharmaceuticals made up 0.15% of ABS Direct Equity Fund's portfolio in Q2 2026, its #92 holding.
  • ABS Direct Equity Fund first reported a position in Mirum Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on ABS Direct Equity Fund's 13F filing for Q2 2026, filed 13 Aug 2026.